PositiveID Corp (OTCMKTS:PSID) a developer company of biological detection and diagnostics applications, announced that it successfully concluded additional testing of its Stage II “Firefly Dx” prototype handheld and real-time PCR pathogen detection system. In the testing, it detected numerous organisms with a multiplex test intended to simultaneously examine for up to four pathogens on the its new Firefly Dx PCR chip.
PositiveID’s Firefly Dx is formulated to get real-time, precise diagnostic outcomes in a handheld device, thereby to be of great use at treatment scenarios, especially at the point of need. As of now, the problem is that there are no existing systems that can offer real-time help. They need lab-based equipment and also longer testing duration extending to or even days to get results. In this phase of multiplex examinations, which is one of the planned benefits of Firefly Dx, PositiveID offered positive PCR results with repeated and consistent discovery of each positive challenge.
PositiveID’s applications include detection of pathogenic organisms, point-of-need, lab-quality; agricultural screening in both developing nations and domestic regions; and detection of biological agents that are accountable for mass destruction. The Company wants to continue examinations of the phase II prototype, which will cover assays designed by the Company and its partners. It also plans to continue to reduce the time to reach result on its PCR chip.
The expert view
William J. Caragol, the Chairman and CEO of PositiveID Corp (OTCMKTS:PSID) said that the feature to quickly examine for numerous organisms from a single sample and locate the reason of symptoms in a patient without conducting several tests will save time as well as money in clinical situations. Most importantly, the real-time product will improve treatment and outcomes. The management is proud of the continued progress and results of the technology and design.
In last trading session, the stock price of PositiveID surged more than 7% to close at $0.0250.